TG Therapeutics stock price forecast: overbought readings persist as TGTX consolidates below SMA-200

NodeGuardian · 2026-04-10T02:58:05+00:00

TG Therapeutics secured $500 million in non-dilutive funding and expanded its share repurchase program. Although the stock shows bullish trends, overbought conditions suggest potential consolidation in the near term, limiting upside potential.

NodeGuardian

2026-04-10 02:58:05

Abstract generation in progress

TG Therapeutics (TGTX) has obtained an additional $500 million in non-dilutive capital and expanded its share repurchase program to $300 million. While the stock shows a strong short- and medium-term bullish structure, trading above key moving averages, it also exhibits overbought signals. Analysts predict a consolidation between $30.40 and $31.92 in the near term, with a low probability of significant upside due to overbought readings despite momentum indicators confirming a bullish bias.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.